These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19949019)

  • 1. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
    Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
    J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
    Hanrahan EO; Ryan AJ; Mann H; Kennedy SJ; Langmuir P; Natale RB; Herbst RS; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3600-9. PubMed ID: 19447868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
    Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
    Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
    Hanrahan EO; Heymach JV
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
    Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
    Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
    Nilsson MB; Giri U; Gudikote J; Tang X; Lu W; Tran H; Fan Y; Koo A; Diao L; Tong P; Wang J; Herbst R; Johnson BE; Ryan A; Webster A; Rowe P; Wistuba II; Heymach JV
    Clin Cancer Res; 2016 Apr; 22(8):1940-50. PubMed ID: 26578684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
    J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
    Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
    Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
    Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Shi Y; Song Y
    Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):e7-e15. PubMed ID: 23177099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
    Heymach JV; Paz-Ares L; De Braud F; Sebastian M; Stewart DJ; Eberhardt WE; Ranade AA; Cohen G; Trigo JM; Sandler AB; Bonomi PD; Herbst RS; Krebs AD; Vasselli J; Johnson BE
    J Clin Oncol; 2008 Nov; 26(33):5407-15. PubMed ID: 18936474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
    Azad AA; Beardsley EK; Hotte SJ; Ellard SL; Klotz L; Chin J; Kollmannsberger C; Mukherjee SD; Chi KN
    Invest New Drugs; 2014 Aug; 32(4):746-52. PubMed ID: 24671507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
    J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
    Annunziata CM; Walker AJ; Minasian L; Yu M; Kotz H; Wood BJ; Calvo K; Choyke P; Kimm D; Steinberg SM; Kohn EC
    Clin Cancer Res; 2010 Jan; 16(2):664-72. PubMed ID: 20068097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
    Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Gastric Cancer; 2017 Jan; 20(1):164-174. PubMed ID: 26681196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
    Sasaki T; Tanno S; Shibukawa K; Osanai S; Kawabe J; Ohsaki Y
    Int J Oncol; 2008 Sep; 33(3):525-32. PubMed ID: 18695882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
    Karoor V; Le M; Merrick D; Dempsey EC; Miller YE
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1141-7. PubMed ID: 20647338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
    Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.